Leerink upgrades Eli Lilly following landmark deal with U.S. government

Leerink Partners upgraded Eli Lilly (LLY) to Outperform, raising its price target to $1,104, citing expectations for significantly increased obesity treatment adoption. This positive outlook is driven by a deal with the U.S. government enabling Medicare coverage for GLP-1s, which could add 40 million potential U.S. candidates. The firm anticipates Eli Lilly will capitalize on this volume expansion through its scale and robust obesity pipeline, including future 'mega-blockbuster' drugs like eloralintide, despite potential pricing impacts.

Analysis

Leerink Partners has upgraded Eli Lilly (LLY) to Outperform, raising its price target to $1,104 from $886, indicating a 19% upside from Friday's close. This positive revision is primarily driven by the anticipated significant increase in obesity treatment adoption, stemming from a deal with the U.S. government that will enable Medicare coverage for GLP-1s for certain patients starting next year. This agreement is projected to expand the potential U.S. candidate pool by 40 million, a substantial increase from the current 8.5 million patients.

The firm anticipates Eli Lilly will successfully execute a "price for volume" strategy, leveraging its considerable scale advantages and expanding obesity portfolio to offset potential pricing impacts. Analyst David Risinger identifies three key pipeline drugs—orforglipron, retatrutide, and eloralintide—as future growth drivers, with eloralintide specifically highlighted as a potential "mega-blockbuster."

These new therapies are expected to fortify LLY's market leadership by offering differentiated solutions across various patient segments, from overweight to severely obese. Additionally, greater ex-U.S. coverage is foreseen as a future catalyst, building on the stock's robust 20% year-to-date performance.

Key Decisions for Investors

• Investors should assess the long-term revenue implications of Eli Lilly's expanded Medicare coverage for GLP-1s, considering the projected 40 million new potential U.S. candidates.
• Monitor the development and market introduction of Eli Lilly's late-stage obesity pipeline, particularly the "mega-blockbuster" potential of eloralintide, as these are critical for sustained growth and market leadership.
• Evaluate the company's execution of its "price for volume" strategy and its ability to maintain profitability amidst increased market penetration and potential pricing dynamics.